-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report . Anticancer Res 2014 ; 34 : 905 – 907 . 17. Suzuki S Sasajima K Miyamoto M . Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal
Search Results
Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib
Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat
Updates to the Management of Kidney Cancer
Eric Jonasch
bevacizumab was compared with sunitinib in 950 patients in the IMmotion 151 trial. 9 Patients were stratified according to MSKCC risk score, liver metastases, and PD-L1 status. Of these, 40% were positive for PD-L1. Median PFS was 11.2 months for the
Updates to the Management of Cutaneous Melanoma
Presented by: Douglas B. Johnson
/kg + nivolumab 1 mg/kg for patients with bulky disease, liver metastases, and/or brain metastases. 1 Those with BRAF mutations who are hospitalized or receiving high doses of opioids may be administered BRAF/MEK inhibitors followed by immunotherapy. “For
Emerging Therapies in the Treatment of Bladder Cancer
Presented by: Arlene O. Siefker-Radtke
liver metastases,” Dr. Siefker-Radtke remarked. “Erdafitinib is a good cytoreducer.” With a longer duration of follow-up, treatment with the selected regimen of erdafitinib continued to demonstrate antitumor activity. 8 Median rates of PFS and OS were
Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
these, 9 had a CCR and elected to be managed nonoperatively; 1 refused recommended surgery despite incomplete tumor regression, and 1 had surgery deferred because of medical comorbidities. One patient developed liver metastases during treatment despite a
Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor–Induced Hepatitis
Michael Li, Danny Wong, Jordan S. Sack, Alexander S. Vogel, F. Stephen Hodi, Lawrence Fong, Jennifer C. Lai, Shilpa Grover, and Stephen D. Zucker
10% of patients receiving combination therapy. 1 , 2 , 8 – 14 The diagnosis of ICI-induced hepatitis requires exclusion of other common causes of acute liver injury (eg, viral hepatitis, liver metastases, biliary obstruction, ischemia, other drugs
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study
Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium
, a patient who undergoes a resection might be diagnosed with liver metastases 3 months after surgery; in the RT group, the same patient would be diagnosed with liver metastases at restaging after RT and would therefore not end up in the resection
Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis
Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu
initially unresectable liver metastases. 26 Notwithstanding that right-sided tumors have a more dismal prognosis than left-sided tumors, several studies have reported favorable survival outcomes after curative-intent hepatectomy even in patients with right
Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich
.91–1.52) ( supplemental eFigures 5 , 6, and 7; supplemental eTable 4 ). Additional contemporary prognostic factors, such as right-side versus left-side primary, KRAS mutation, and liver metastases, were available only for the RAISE trial. Hence, an exploratory
Challenges in the Management of Older Patients With Colon Cancer
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
with early-stage colon cancer. Issues in the Treatment of Metastatic Colon Cancer in Older Patients Surgical Considerations Early studies evaluating the surgical resection of liver metastases in colorectal cancer reported an increase in
